You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1
Inseong Hwang
 -- 2378 2022-04-04 03:06:12 |
2 format
Bruce Ren
 -3 word(s) 2375 2022-04-06 02:58:38 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Hwang, I.; , . Links between Oral Pathogens and Systemic Diseases. Encyclopedia. Available online: https://encyclopedia.pub/entry/21339 (accessed on 18 July 2025).
Hwang I,  . Links between Oral Pathogens and Systemic Diseases. Encyclopedia. Available at: https://encyclopedia.pub/entry/21339. Accessed July 18, 2025.
Hwang, Inseong, . "Links between Oral Pathogens and Systemic Diseases" Encyclopedia, https://encyclopedia.pub/entry/21339 (accessed July 18, 2025).
Hwang, I., & , . (2022, April 04). Links between Oral Pathogens and Systemic Diseases. In Encyclopedia. https://encyclopedia.pub/entry/21339
Hwang, Inseong and . "Links between Oral Pathogens and Systemic Diseases." Encyclopedia. Web. 04 April, 2022.
Links between Oral Pathogens and Systemic Diseases
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells11071079

The oral cavity is the gateway for microorganisms into your body where they disseminate not only to the directly connected respiratory and digestive tracts but also to the many remote organs. Oral microbiota, travelling to the end of the intestine and circulating in our bodies through blood vessels, not only affect a gut microbiome profile but also lead to many systemic diseases. 

biofilm gingival sulcus junctional epithelium leaky gum leaky gut mucosal barrier oral microbiome systemic disease

1. Introduction

Humans internalize the microbiota of this planet through the oral cavity, either temporarily or permanently. The oral cavity harbours the second most abundant microorganisms after the gastrointestinal (GI) tract in a variety of distinct habitats, such as teeth, tongue, gingival sulcus (GS), palate, saliva, buccal mucosa, and throat. The expanded Human Oral Microbiome Database (eHOMD v3, http://homd.org, accessed on 16 February 2022) established during the Human Microbiome Project enlists at least 774 microbial species to date.
As the old dogma that the lungs and placenta are sterile becomes obsolete [1][2][3][4][5], the oral microbiota has proven to be the primary source of the bacterial microbiota in human organs [6]. For one, microaspiration during respiratory activity, such as oral breathing, affects the lung microbiota [7]. In addition, dietary patterns dynamically affect the microbiome profile of the GI tract either by microbial contamination or by supplying specific nutrients for microbial commensals, even manipulating the pathophysiology of cancerous diseases [8][9] as well as regulating immune responses across the gut–brain axis [10][11]. As such, along with the revolution of human microbiome research, much effort has been dedicated to figuring out the relationship between the oral and gut microbiota, which has been dubbed the “oral–gut–brain axis” [12][13][14][15][16][17].
The microbiota in the gut seek opportunities to breach the dysfunctional gut mucosal barrier to reach the underlying immune system, resulting in “leaky gut” syndrome. This type of leak occurs through the cellular junctions between the intestinal epithelia. In the oral cavity, the microbes can easily colonize on the surface of the hard tissue of the tooth enamel to form biofilm and remain sclerotized until proper interventions come in. The growing body of the biofilm not only acts as a wedge disjoining the tooth and the gingiva, enlarging the GS depth but also deploys an ample number of microbes near the sulcus epithelium, enhancing the opportunity for microbial infiltration into the oral mucosa [18]. Thus, microbial infection in the oral cavity is accelerated by both physical and biological processes.

2. Oral Pathogens and Systemic Diseases

The origin of bacteria found in remote organs converges to the oral cavity [19][20][21][22] (Figure 1). For example, the placental microbiome profiles were most comparable to those of the oral microbiome [1]. The overlap of the unique members of oral microbes with other remote organs is consistent with previous clinical studies in which Fusobacterium nucleatum, a Gram-negative oral anaerobe, was clinically suspected to be a major risk factor in colorectal cancer [23][24][25], oral squamous cell carcinoma (OSCC) [26], and in preterm and term stillbirth [27][28]. Likewise, an infamous oral pathogenic bacterium, Porphyromonas gingivalis, is related to pancreatic cancer [29], colorectal cancer [30][31][32], liver health [33], rheumatoid arthritis [34][35], diabetes [36][37][38], OSCC [39][40], and neurodegenerative diseases [41][42][43][44][45][46][47][48][49]. In the case of atherosclerotic CVD, when the vascular tissues of the coronary and femoral arteries of the patients with CVD were examined, P. gingivalis was found in 42 out of 42 patients [50]. Thus, previously explained by the passive accumulation of fat, the aetiology of CVD is now leaning toward inflammatory responses of the vascular endothelium [51][52]. Notably, live P. gingivalis is known to traffic into endoplasmic reticulum-rich autophagosomes [53] and target host ectonucleotidase-CD73 [54] for its chronic survival, replication, and persistence in the dysbiotic human gingival epithelia [55].
Cells 11 01079 g003 550
Figure 1. The oral cavity as the origin of the internal microbiome in humans. The microbiome in the oral cavity can disseminate to the remote sites of the body, such as the brain, stomach, intestines, and heart, via hematogenous and enteric pathways. The PP, a pathologically deepened GS due to microbial infection and colonization, gradually allows detachment of the connective tissues of the JE from the tooth surface. The epithelial layer of the apical JE is thin enough for bacterial virulence factors as well as pathogenic bacteria, such as P. gingivalis, to infiltrate into the bloodstream, resulting in a leaky gum syndrome. The microbiome of the oral cavity also affects gut microbiome profiles by moving through the gastrointestinal tract, causing a variety of gut-related diseases, such as IBD, IBS, and colon cancer.
Recently, Kitamoto et al. demonstrated the mechanistic underpinnings by which periodontal inflammation due to oral infection contributes to the pathogenesis of extra-oral diseases [12]. In this elaborated study using mice, they showed that periodontitis aggravates gut inflammation by translocating oral Klebsiella/Enterobacter species to the lower digestive tract where it colonizes ectopically to elicit colitis through IL-1β. In parallel, oral Th17 cells induced by oral pathobiont expansion migrate to the gut and promote colitis, constituting both microbial and immunological pathways that link oral and gut health. Furthermore, Dong et al. showed that the alterations of the oral microbiota, especially F. nucleatum colonization in CRC locus, can change the gut bacterial composition within tumours and influence the therapeutic efficacy and prognosis of radiotherapy for primary rectal cancer and CRC liver metastases in mouse models [56]. Kartal et al. applied shotgun metagenomic and 16S rRNA sequencing to faecal and saliva samples from pancreatic ductal adenocarcinoma (PDAC) to identify diagnostic classifiers [22]. While proving that the faecal metagenomic classifiers outperformed the saliva-based classifiers, they also confirmed that the strains of faecal PDAC-associated microbes originate from the oral cavity. Thus, the growing body of examples that show the close relationship of oral pathogens with a variety of systemic diseases enabled the introduction of the term “periodontal medicine”, to describe how periodontal infection and inflammation affect extraoral illness [57][58]. As such, the oral cavity needs to be re-evaluated as a more pivotal organ with the revolution of microbiology in the 21st century [59].
There are many disease model systems proving that oral bacteria induce systemic diseases, such as CVD, type II diabetes mellitus (T2DM), OSCC, and AD (Table 1). For one, the infection of aortic lesions with P. gingivalis activates adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), leading to chronic inflammation via the migration of more immune cells to the lesion sites [60]. The microarray analysis demonstrated that P. gingivalis-treated human aortic endothelial cells (HAECs) upregulated expression levels of ICAM-1, VCAM-1, and interleukin-6 (IL-6). As well as ICAM-1 and VCAM-1 upregulation, pathological enlargement of the atherosclerotic lesion area was well demonstrated in hyperlipidemic (Apoe−/−) mice orally challenged with P. gingivalis [60][61]. As an effective molecule, lipopolysaccharide from P. gingivalis (PgLPS) was established to promote inflammatory response by increasing mononuclear cell adhesion to human umbilical vein endothelial cells (HUVECs) via ICAM-1 and Toll-like receptor 2 (TLR-2)-dependent mechanism [62]. Subcutaneous infection of obese pigs with P. gingivalis also showed enhanced aortic and coronary arterial atherosclerosis [63]. In addition to P. gingivalis, intravenous infection of hyperlipidemic mice with Aggregatibacter actinomycetemcomitans can promote and accelerate atherosclerotic plaques [64] and time-dependently elevate matrix metalloproteinase-9 (MMP-9) expression [65]. The MMP-9, derived from macrophages, has been highlighted as a risk factor for acute atherosclerosis due to its proteolytic activity in advanced atherosclerotic plaque rupture [66].
Table 1. The systemic disease models induced by oral pathogens.
  Oral Pathogens Models Infection Methods Experimental Results Year Ref.
Atherosclerotic CVD In vitro P. gingivalis 381 HAECs 6 h infection Increased ICAM-1, VCAM-1, and IL-6 expression 2005 [60]
P. gingivalis ATCC33277-driven PgLPS HUVECs 24 h infection Increased adhesion of mononuclear cells to HUVECs via ICAM-1 and TLR-2 dependent mechanism. 2008 [62]
In vivo P. gingivalis 381 Apoe−/− mice
  • Infected (n = 25)
  • Non-infected (n = 25)
 Oral infection 5 times per week over 3 weeks Increased aortic atherosclerosis. 2003 [61]
P. gingivalis 381 Apoe−/− mice
  • Infected (n = 6)
  • Non-infected (n = 6)
 Oral infection 5 times per week over 3 weeks Increased aortic ICAM-1, VCAM-1 immunostaining. 2005 [60]
P. gingivalis 381 or A7436 Pigs
  • Infected (n = 23)
  • Non-infected (n = 13)
 Subcutaneously infection 3 times per week for 5 months Increased aortic and coronary arterial atherosclerosis. 2005 [63]
A. actinomycetemcomitans AT445b Apoe−/− mice
  • Infected (n = 9)
  • Non-infected (n = 9)
 Intravenous infection once a week for 4, 6, or 8 weeks Increased aortic MMP-9 expression and serum CRP. 2008 [65]
A. actinomycetemcomitans HK1651 Apoeshl mice
  • Infected (n = 6)
  • Non-infected (n = 6)
 Intravenous infection 3 times per week over 3 weeks Increased atherosclerotic plaque, serum C-reactive protein (CRP), IL-6, and aortic ICAM-1. 2014 [67]
T2DM In vivo P. gingivalis W83 Mice Oral infection twice per week for 5 weeks Increased gut dysbiosis, gut barrier invasion, serum endotoxin, insulin resistance. 2014 [67]
P. gingivalis ATCC33277,
F. nucleatum,
P. intermedia		 Mice
  • Infected (n = 16)
  • Non-infected (n = 13)
 Oral infection 4 times a week for 4 weeks, thereafter normal diet or HFD-fed for additional 3 months Increased periodontal dysbiosis, insulin resistance in HFD-fed mice. 2017 [68]
P. gingivalis ATCC33277 (WT) or ∆bcat Mice
  • WT infected (n = 6)
  • ∆bcat infected (n = 6)
  • Non-infected (n = 6)
 Oral infection twice per week for 4 weeks concomitantly HFD-fed P. gingivalis (∆bcat) cannot induce insulin resistance in HFD-fed mice. 2020 [69]
OSCC In vivo P. gingivalis 381 Mice
  • Infected (n = 15)
  • 4NQO-treated (n = 20)
  • 4NQO-treated + infected (n = 20)
  • Control (n = 10)
 4NQO treatment for 8 weeks, thereafter oral infection with P. gingivalis for 8 weeks Enhanced OSCC induction and dysregulated lipid metabolism in 4NQO-treated mice. 2018 [39]
P. gingivalis ATCC33277 Mice
  • 4NQO-treated + infected (n = 12)
  • Non-infected (n = 6)
 4NQO treatment for 16 weeks, thereafter oral infection with P. gingivalis for 10 weeks Enhanced OSCC induction and increased infiltration of CD11b+ MDSCs in 4NQO-treated mice. 2020 [40]
AD In vitro P. gingivalis ATCC33277 Immortalized mouse microglial cell line MG6 3, 6, or 12 h infection of P. gingivalis in the presence and absence of KYT1 (Rgp inhibitor) and KYT36 (Kgp inhibitor) Increased expression levels of IL-6 and TNF-α, which were inhibited by KYT1 and KYT36 treatment. 2017 [70]
PgLPS Rat brain neonatal microglia 18 h infection Activated microglial release of cytokine TNF-α, IL-6, and MMP-9. 2020 [71]
In vivo P. gingivalis 381, Treponema denticola ATCC 35404, Tannerella forsythia ATCC 43037, and F. nucleatum ATCC 49256 Apoe−/− mice
  • Mono-infected (n = 12)
  • Multi-infected (n = 12)
  • Non-infected (n = 12)
 Oral infection for 24 weeks P. gingivalis genomic DNA was detected in mice brains (9 out of 12 at 24 weeks). 2015 [72]
P. gingivalis ATCC33277 APP transgenic mice
  • Infected (n = 14)
  • Non-infected (n = 12)
 Gingival infection Exacerbated Aβ plaques and inflammatory cytokines in the brain of AD mouse model. 2017 [73]
PgLPS Mice
  • Young WT mice (2 months, n = 6)
  • Middle-aged WT mice (12 months, n = 6)
  • Young Catb−/− mice (n = 6)
  • Middle-aged Catb−/− mice (n = 6)
 Intraperitoneal infection daily for 5 weeks PgLPS induced learning and memory deficit in middle-aged WT mice, but not in young WT, young Catb−/−, and middle-aged Catb−/− mice. 2017 [74]
P. gingivalis ATCC33277,
Kgp-deficient P. gingivalis KDP129		 Cx3cr1+/GFP mice Injection of P. gingivalis into the somatosensory cortex of mice GFP+ microglia accumulated around the injection site of P. gingivalis, but not of KDP129. 2017 [70]
PgLPS Rats (n = 6) Palatal gingival infection 3 times for 2 weeks Induced alveolar bone loss and increased serum Aβ levels. 2019 [70][75]
P. gingivalis ATCC33277 Rats
  • Infected for 4 weeks (n = 10)
  • Non-infected for 4 weeks (n = 10)
  • Infected for 12 weeks (n = 10)
  • Non-infected for 12 weeks (n = 10)
 Intravenous infection 3 times a week for 4 or 12 weeks Induced tau hyperphosphorylation (pTau181 and pTau231) in the rat hippocampus. 2021 [76]
T2DM is a highly prevalent metabolic disease characterized by prolonged high glucose levels in the blood. Insulin resistance on peripheral tissues has been focused on as the major causing factor of T2DM [77]. Recently, many microbiologists designated gut dysbiosis as a critical factor of insulin resistance development in T2DM accompanied by gut barrier dysfunction [78]. Interestingly, oral infection of mice with P. gingivalis can also induce gut dysbiosis, leading to insulin resistance via a pathway through endotoxin entrance and chronic inflammation [67]. Mice pre-treated with P. gingivalis, F. nucleatum, and Prevotella intermedia showed accelerated insulin resistance after three months of high-fat diet (HFD) feeding [68]. The branched-chain amino acid (BCAA) biosynthesis activity of P. gingivalis is a suggested mechanism of insulin resistance development, as evident that BCAA aminotransferase-deficient (∆bcat) P. gingivalis strain can neither induce insulin resistance nor upregulate serum BCAA in HFD mice model [69].
OSCC is the most malignant cancer of the oral cavity with an increasing rate of incidence, and the risk factors for OSCC include alcohol consumption, smoke, and human papillomavirus [79]. Interestingly, two independent groups suggested that P. gingivalis administration can significantly increase the number and diameter of the lesions in tongue tissues of mice pre-treated with carcinogen 4-nitroquinoline-1 oxide (4NQO). They provided two pathways, dysregulated lipid metabolism and CD11b+ myeloid-derived suppressor cells (MDSCs) infiltration, involved with OSCC deterioration by the pathogen [39][40]. Indeed, abnormal lipid regulation by increased expressions of fatty acid-binding protein 4 (FABP4) and FABP5 has been reported to have a crucial role in OSCC development via activation of mitogen-activated protein kinase (MAPK) pathway and MMP-9 [80][81]. By contrast, CD11b+ is responsible for MDSCs migration to the tumour microenvironment where the cells have an immunosuppressive role that favours tumour progression [82].
AD is one of the representative neurodegenerative diseases diagnosed with senile plaques and abundant neurofibrillary tangles, which can be deteriorated by oral pathogenic infection. Gingival-infected P. gingivalis was reported to exacerbate the accumulation of Aβ plaques and inflammatory cytokines in brain specimens of amyloid precursor protein (APP) transgenic mice [73]. Interestingly, the anatomic analysis demonstrated that P. gingivalis genomic DNA was detected in brain specimens of 9 out of 12 Apoe−/− mice orally challenged with P. gingivalis for 24 weeks [72], implicating that P. gingivalis can penetrate the gum and enter the blood-brain barrier (BBB). The result that intravenous injection of P. gingivalis into rats enhanced tau hyperphosphorylation in the hippocampus can reinforce the theory of BBB penetration of P. gingivalis [76]. As similar atherosclerotic CVD, PgLPS has also been designated as P. gingivalis-driven virulence factor affecting AD. It was reported that PgLPS treatment to rat brain neonatal microglial cells promoted the release of inflammatory mediators such as TNF-α and IL-6 [71], and palatal gingival infection of PgLPS into rats induced alveolar bone loss and increased serum Aβ levels [75]. Middle-aged wild-type (WT) mice intraperitoneally challenged with PgLPS for 5 weeks represented learning and memory deficit and microglia-mediated neuroinflammation, although age-matched mice deficient for cathepsin B (Catb−/−) were insensitive to PgLPS [74]. In addition to PgLPS, gingipain is an AD virulence factor, a unique class of cysteine proteinase that comprises Lys-gingipain (Kgp) and Arg-gingipain (Rgp). The modulatory role of the gingipain on neuroinflammation was well-established using Kgp and Rgp inhibitors (KYT1 and KYT36, respectively) or P. gingivalis KDP129, a gingipain-deficient mutant strain [70]. KYT1 and KYT36 treatment effectively inhibited P. gingivalis-driven increased expression of IL-6 and TNF-α in immortalized mouse microglial cell line MG6. Injection of P. gingivalis, but not KDP129 strain, into the somatosensory cortex of mice can recruit microglia to the injection site, revealing that gingipain is the effective factor for microglial migration and accumulation around P. gingivalis in the brain [70].

References

  1. Aagaard, K.; Ma, J.; Antony, K.M.; Ganu, R.; Petrosino, J.; Versalovic, J. The placenta harbors a unique microbiome. Sci. Transl. Med. 2014, 6, 237ra265.
  2. Gomez-Arango, L.F.; Barrett, H.L.; McIntyre, H.D.; Callaway, L.K.; Morrison, M.; Nitert, M.D. Contributions of the maternal oral and gut microbiome to placental microbial colonization in overweight and obese pregnant women. Sci. Rep. 2017, 7, 2860.
  3. Goffau, M.C.d.; Lager, S.; Sovio, U.; Gaccioli, F.; Cook, E.; Peacock, S.J.; Parkhill, J.; Charnock-Jones, D.S.; Smith, G.C.S. Human placenta has no microbiome but can contain potential pathogens. Nature 2019, 572, 329–334.
  4. Ye, C.; Kapila, Y. Oral microbiome shifts during pregnancy and adverse pregnancy outcomes: Hormonal and Immunologic changes at play. Periodontol. 2000 2021, 87, 276–281.
  5. Whiteside, S.A.; McGinniss, J.E.; Collman, R.G. The lung microbiome: Progress and promise. J. Clin. Investig. 2021, 131, e150473.
  6. Huffnagle, G.B.; Dickson, R.P.; Lukacs, N.W. The respiratory tract microbiome and lung inflammation: A two-way street. Mucosal Immunol. 2017, 10, 299–306.
  7. Dickson, R.P.; Erb-Downward, J.R.; Freeman, C.M.; McCloskey, L.; Falkowski, N.R.; Huffnagle, G.B.; Curtis, J.L.; Clemente, J.C.; Molyneaux, P.; Bogaert, D. Bacterial Topography of the Healthy Human Lower Respiratory Tract. MBio 2017, 8, e02287-16.
  8. Mehta, R.S.; Nishihara, R.; Cao, Y.; Song, M.; Mima, K.; Qian, Z.R.; Nowak, J.A.; Kosumi, K.; Hamada, T.; Masugi, Y.; et al. Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. JAMA Oncol. 2017, 3, 921–927.
  9. Tao, J.; Li, S.; Gan, R.-Y.; Zhao, C.-N.; Meng, X.; Li, H.-B. Targeting gut microbiota with dietary components on cancer: Effects and potential mechanisms of action. Crit. Rev. Food Sci. Nutr. 2020, 60, 1025–1037.
  10. Agirman, G.; Yu, K.B.; Hsiao, E.Y. Signaling inflammation across the gut-brain axis. Science 2021, 374, 1087–1092.
  11. Morais, L.H.; Schreiber, H.L.; Mazmanian, S.K. The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 2021, 19, 241–255.
  12. Kitamoto, S.; Nagao-Kitamoto, H.; Jiao, Y.; Gillilland, M.G.; Hayashi, A.; Imai, J.; Sugihara, K.; Miyoshi, M.; Brazil, J.C.; Kuffa, P.; et al. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell 2020, 182, 447–462.e14.
  13. Kitamoto, S.; Nagao-Kitamoto, H.; Hein, R.; Schmidt, T.M.; Kamada, N. The Bacterial Connection between the Oral Cavity and the Gut Diseases. J. Dent. Res. 2020, 99, 1021–1029.
  14. Ray, K. The oral–gut axis in IBD. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 532.
  15. Narengaowa; Kong, W.; Lan, F.; Awan, U.F.; Qing, H.; Ni, J. The Oral–Gut–Brain AXIS: The Influence of Microbes in Alzheimer’s Disease. Front. Cell. Neurosci. 2021, 15, 113.
  16. Byrd, K.M.; Gulati, A.S. The “Gum–Gut” Axis in Inflammatory Bowel Diseases: A Hypothesis-Driven Review of Associations and Advances. Front. Immunol. 2021, 12, 620124.
  17. Hu, S.; Png, E.; Gowans, M.; Ong, D.E.H.; de Sessions, P.F.; Song, J.; Nagarajan, N. Ectopic gut colonization: A metagenomic study of the oral and gut microbiome in Crohn’s disease. Gut Pathog. 2021, 13, 13.
  18. Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P. Bacterial biofilms: From the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004, 2, 95–108.
  19. Fardini, Y.; Chung, P.; Dumm, R.; Joshi, N.; Han, Y.W. Transmission of diverse oral bacteria to murine placenta: Evidence for the oral microbiome as a potential source of intrauterine infection. Infect. Immun. 2010, 78, 1789–1796.
  20. Kumar, P.S. From focal sepsis to periodontal medicine: A century of exploring the role of the oral microbiome in systemic disease. J. Physiol. 2017, 595, 465–476.
  21. Kleinstein, S.; Nelson, K.; Freire, M. Inflammatory networks linking oral microbiome with systemic health and disease. J. Dent. Res. 2020, 99, 1131–1139.
  22. Kartal, E.; Schmidt, T.S.B.; Molina-Montes, E.; Rodríguez-Perales, S.; Wirbel, J.; Maistrenko, O.M.; Akanni, W.A.; Alashkar Alhamwe, B.; Alves, R.J.; Carrato, A.; et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022.
  23. Wu, J.; Li, Q.; Fu, X. Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity. Transl. Oncol. 2019, 12, 846–851.
  24. Casasanta, M.A.; Yoo, C.C.; Udayasuryan, B.; Sanders, B.E.; Umaña, A.; Zhang, Y.; Peng, H.; Duncan, A.J.; Wang, Y.; Li, L.; et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci. Signal. 2020, 13, eaba9157.
  25. Loftus, M.; Hassouneh, S.A.-D.; Yooseph, S. Bacterial community structure alterations within the colorectal cancer gut microbiome. BMC Microbiol. 2021, 21, 98.
  26. Zhang, S.; Li, C.; Zhang, Z.; Li, Y.; Li, Q.; Geng, F.; Liu, J.; Pan, Y. Analysis of differentially expressed genes in oral epithelial cells infected with Fusobacterium nucleatum for revealing genes associated with oral cancer. J. Cell. Mol. Med. 2021, 25, 892–904.
  27. Han, Y.W.; Redline, R.W.; Li, M.; Yin, L.; Hill, G.B.; McCormick, T.S. Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: Implication of oral bacteria in preterm birth. Infect. Immun. 2004, 72, 2272–2279.
  28. Vander Haar, E.L.; So, J.; Gyamfi-Bannerman, C.; Han, Y.W. Fusobacterium nucleatum and adverse pregnancy outcomes: Epidemiological and mechanistic evidence. Anaerobe 2018, 50, 55–59.
  29. Fan, X.; Alekseyenko, A.V.; Wu, J.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Abnet, C.C.; Stolzenberg-Solomon, R.; Miller, G.; et al. Human oral microbiome and prospective risk for pancreatic cancer: A population-based nested case-control study. Gut 2018, 67, 120–127.
  30. Okumura, S.; Konishi, Y.; Narukawa, M.; Sugiura, Y.; Yoshimoto, S.; Arai, Y.; Sato, S.; Yoshida, Y.; Tsuji, S.; Uemura, K.; et al. Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion. Nat. Commun. 2021, 12, 5674.
  31. Wang, X.; Jia, Y.; Wen, L.; Mu, W.; Wu, X.; Liu, T.; Liu, X.; Fang, J.; Luan, Y.; Chen, P.; et al. Porphyromonas gingivalis Promotes Colorectal Carcinoma by Activating the Hematopoietic NLRP3 Inflammasome. Cancer Res. 2021, 81, 2745–2759.
  32. Chen, Y.; Huang, Z.; Tang, Z.; Huang, Y.; Huang, M.; Liu, H.; Ziebolz, D.; Schmalz, G.; Jia, B.; Zhao, J. More Than Just a Periodontal Pathogen–the Research Progress on Fusobacterium nucleatum. Front. Cell. Infect. Microbiol. 2022, 12, 64.
  33. Mohammed, H.; Varoni, E.; Cochis, A.; Cordaro, M.; Gallenzi, P.; Patini, R.; Staderini, E.; Lajolo, C.; Rimondini, L.; Rocchetti, V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018, 6, 115.
  34. Flak, M.B.; Colas, R.A.; Muñoz-Atienza, E.; Curtis, M.A.; Dalli, J.; Pitzalis, C. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis. JCI Insight 2019, 4, e125191.
  35. Reyes, L. Porphyromonas gingivalis. Trends Microbiol. 2021, 29, 376–377.
  36. Wang, J.; Qi, J.; Zhao, H.; He, S.; Zhang, Y.; Wei, S.; Zhao, F. Metagenomic sequencing reveals microbiota and its functional potential associated with periodontal disease. Sci. Rep. 2013, 3, 1843.
  37. Padmalatha, G.; Bavle, R.; Satyakiran, G.; Paremala, K.; Sudhakara, M.; Makarla, S. Quantification of Porphyromonas gingivalis in chronic periodontitis patients associated with diabetes mellitus using real-time polymerase chain reaction. J. Oral Maxillofac. Pathol. 2016, 20, 413–418.
  38. Matsha, T.E.; Prince, Y.; Davids, S.; Chikte, U.; Erasmus, R.T.; Kengne, A.P.; Davison, G.M. Oral Microbiome Signatures in Diabetes Mellitus and Periodontal Disease. J. Dent. Res. 2020, 99, 658–665.
  39. Wu, J.S.; Zheng, M.; Zhang, M.; Pang, X.; Li, L.; Wang, S.S.; Yang, X.; Wu, J.B.; Tang, Y.J.; Tang, Y.L.; et al. Porphyromonas gingivalis Promotes 4-Nitroquinoline-1-Oxide-Induced Oral Carcinogenesis With an Alteration of Fatty Acid Metabolism. Front. Microbiol. 2018, 9, 2081.
  40. Wen, L.; Mu, W.; Lu, H.; Wang, X.; Fang, J.; Jia, Y.; Li, Q.; Wang, D.; Wen, S.; Guo, J.; et al. Porphyromonas gingivalis Promotes Oral Squamous Cell Carcinoma Progression in an Immune Microenvironment. J. Dent. Res. 2020, 99, 666–675.
  41. Dominy, S.S.; Lynch, C.; Ermini, F.; Benedyk, M.; Marczyk, A.; Konradi, A.; Nguyen, M.; Haditsch, U.; Raha, D.; Griffin, C.; et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 2019, 5, eaau3333.
  42. Elwishahy, A.; Antia, K.; Bhusari, S.; Ilechukwu, N.C.; Horstick, O.; Winkler, V. Porphyromonas Gingivalis as a Risk Factor to Alzheimer’s Disease: A Systematic Review. J. Alzheimers Dis. Rep. 2021, 5, 721–732.
  43. Nara, P.L.; Sindelar, D.; Penn, M.S.; Potempa, J.; Griffin, W.S.T. Porphyromonas gingivalis Outer Membrane Vesicles as the Major Driver of and Explanation for Neuropathogenesis, the Cholinergic Hypothesis, Iron Dyshomeostasis, and Salivary Lactoferrin in Alzheimer’s Disease. J. Alzheimers Dis. 2021, 82, 1417–1450.
  44. Zhang, Z.; Liu, D.; Liu, S.; Zhang, S.; Pan, Y. The Role of Porphyromonas gingivalis Outer Membrane Vesicles in Periodontal Disease and Related Systemic Diseases. Front. Cell. Infect. Microbiol. 2021, 10, 585917.
  45. Patel, S.; Howard, D.; Chowdhury, N.; Derieux, C.; Wellslager, B.; Yilmaz, Ö.; French, L. Characterization of Human Genes Modulated by Porphyromonas gingivalis Highlights the Ribosome, Hypothalamus, and Cholinergic Neurons. Front. Immunol. 2021, 12, 2165.
  46. Riviere, G.R.; Riviere, K.; Smith, K. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer’s disease. Oral Microbiol. Immunol. 2002, 17, 113–118.
  47. Hajishengallis, G. Immunomicrobial pathogenesis of periodontitis: Keystones, pathobionts, and host response. Trends Immunol. 2014, 35, 3–11.
  48. Hajishengallis, G.; Lamont, R.J. Dancing with the stars: How choreographed bacterial interactions dictate nososymbiocity and give rise to keystone pathogens, accessory pathogens, and pathobionts. Trends Microbiol. 2016, 24, 477–489.
  49. Costa, M.J.F.; Araújo, I.D.T.d.; Alves, L.d.R.; Silva, R.L.d.; Calderon, P.d.S.; Borges, B.C.D.; Martins, A.R.L.d.A.; Gurgel, B.C.d.V.; Lins, R.D.A.U. Relationship of Porphyromonas gingivalis and Alzheimer’s disease: A systematic review of pre-clinical studies. Clin. Oral Investig. 2021, 25, 797–806.
  50. Mougeot, J.L.C.; Stevens, C.B.; Paster, B.J.; Brennan, M.T.; Lockhart, P.B.; Mougeot, F.K.B. Porphyromonas gingivalis is the most abundant species detected in coronary and femoral arteries. J. Oral Microbiol. 2017, 9, 1281562.
  51. Slocum, C.; Kramer, C.; Genco, C. Immune dysregulation mediated by the oral microbiome: Potential link to chronic inflammation and atherosclerosis. J. Intern. Med. 2016, 280, 114–128.
  52. Farrugia, C.; Stafford, G.P.; Potempa, J.; Wilkinson, R.N.; Chen, Y.; Murdoch, C.; Widziolek, M. Mechanisms of vascular damage by systemic dissemination of the oral pathogen Porphyromonas gingivalis. FEBS J. 2021, 288, 1479–1495.
  53. Lee, K.; Roberts, J.S.; Choi, C.H.; Atanasova, K.R.; Yilmaz, Ö. Porphyromonas gingivalis traffics into endoplasmic reticulum-rich-autophagosomes for successful survival in human gingival epithelial cells. Virulence 2018, 9, 845–859.
  54. Lee, J.S.; Chowdhury, N.; Roberts, J.S.; Yilmaz, Ö. Host surface ectonucleotidase-CD73 and the opportunistic pathogen, Porphyromonas gingivalis, cross-modulation underlies a new homeostatic mechanism for chronic bacterial survival in human epithelial cells. Virulence 2020, 11, 414–429.
  55. Lee, J.S.; Spooner, R.; Chowdhury, N.; Pandey, V.; Wellslager, B.; Atanasova, K.R.; Evans, Z.; Yilmaz, Ö. In Situ Intraepithelial Localizations of Opportunistic Pathogens, Porphyromonas gingivalis and Filifactor alocis, in Human Gingiva. Curr. Res. Microb. Sci. 2020, 1, 7–17.
  56. Dong, J.; Li, Y.; Xiao, H.; Zhang, S.; Wang, B.; Wang, H.; Li, Y.; Fan, S.; Cui, M. Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models. Cell Rep. 2021, 37, 109866.
  57. Pizzo, G.; Guiglia, R.; Russo, L.L.; Campisi, G. Dentistry and internal medicine: From the focal infection theory to the periodontal medicine concept. Eur. J. Intern. Med. 2010, 21, 496–502.
  58. Beck, J.D.; Papapanou, P.N.; Philips, K.H.; Offenbacher, S. Periodontal Medicine: 100 Years of Progress. J. Dent. Res. 2019, 98, 1053–1062.
  59. Sharma, N.; Bhatia, S.; Sodhi, A.S.; Batra, N. Oral microbiome and health. AIMS Microbiol. 2018, 4, 42–66.
  60. Chou, H.H.; Yumoto, H.; Davey, M.; Takahashi, Y.; Miyamoto, T.; Gibson, F.C., 3rd; Genco, C.A. Porphyromonas gingivalis fimbria-dependent activation of inflammatory genes in human aortic endothelial cells. Infect. Immun. 2005, 73, 5367–5378.
  61. Lalla, E.; Lamster, I.B.; Hofmann, M.A.; Bucciarelli, L.; Jerud, A.P.; Tucker, S.; Lu, Y.; Papapanou, P.N.; Schmidt, A.M. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1405–1411.
  62. Nakamura, N.; Yoshida, M.; Umeda, M.; Huang, Y.; Kitajima, S.; Inoue, Y.; Ishikawa, I.; Iwai, T. Extended exposure of lipopolysaccharide fraction from Porphyromonas gingivalis facilitates mononuclear cell adhesion to vascular endothelium via Toll-like receptor-2 dependent mechanism. Atherosclerosis 2008, 196, 59–67.
  63. Brodala, N.; Merricks, E.P.; Bellinger, D.A.; Damrongsri, D.; Offenbacher, S.; Beck, J.; Madianos, P.; Sotres, D.; Chang, Y.-L.; Koch, G.; et al. Porphyromonas gingivalis Bacteremia Induces Coronary and Aortic Atherosclerosis in Normocholesterolemic and Hypercholesterolemic Pigs. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1446–1451.
  64. Zhang, T.; Kurita-Ochiai, T.; Hashizume, T.; Du, Y.; Oguchi, S.; Yamamoto, M. Aggregatibacter actinomycetemcomitans accelerates atherosclerosis with an increase in atherogenic factors in spontaneously hyperlipidemic mice. FEMS Immunol. Med. Microbiol. 2010, 59, 143–151.
  65. Tuomainen, A.M.; Jauhiainen, M.; Kovanen, P.T.; Metso, J.; Paju, S.; Pussinen, P.J. Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb. Pathog. 2008, 44, 111–117.
  66. Gough, P.J.; Gomez, I.G.; Wille, P.T.; Raines, E.W. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Investig. 2006, 116, 59–69.
  67. Arimatsu, K.; Yamada, H.; Miyazawa, H.; Minagawa, T.; Nakajima, M.; Ryder, M.I.; Gotoh, K.; Motooka, D.; Nakamura, S.; Iida, T.; et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci. Rep. 2014, 4, 4828.
  68. Blasco-Baque, V.; Garidou, L.; Pomié, C.; Escoula, Q.; Loubieres, P.; Le Gall-David, S.; Lemaitre, M.; Nicolas, S.; Klopp, P.; Waget, A.; et al. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut 2017, 66, 872–885.
  69. Tian, J.; Liu, C.; Zheng, X.; Jia, X.; Peng, X.; Yang, R.; Zhou, X.; Xu, X. Porphyromonas gingivalis Induces Insulin Resistance by Increasing BCAA Levels in Mice. J. Dent. Res. 2020, 99, 839–846.
  70. Liu, Y.; Wu, Z.; Nakanishi, Y.; Ni, J.; Hayashi, Y.; Takayama, F.; Zhou, Y.; Kadowaki, T.; Nakanishi, H. Infection of microglia with Porphyromonas gingivalis promotes cell migration and an inflammatory response through the gingipain-mediated activation of protease-activated receptor-2 in mice. Sci. Rep. 2017, 7, 11759.
  71. Memedovski, Z.; Czerwonka, E.; Han, J.; Mayer, J.; Luce, M.; Klemm, L.C.; Hall, M.L.; Mayer, A.M.S. Classical and Alternative Activation of Rat Microglia Treated with Ultrapure Porphyromonas gingivalis Lipopolysaccharide In Vitro. Toxins 2020, 12, 333.
  72. Poole, S.; Singhrao, S.K.; Chukkapalli, S.; Rivera, M.; Velsko, I.; Kesavalu, L.; Crean, S. Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/- mice brains. J. Alzheimers Dis. 2015, 43, 67–80.
  73. Ishida, N.; Ishihara, Y.; Ishida, K.; Tada, H.; Funaki-Kato, Y.; Hagiwara, M.; Ferdous, T.; Abdullah, M.; Mitani, A.; Michikawa, M.; et al. Periodontitis induced by bacterial infection exacerbates features of Alzheimer’s disease in transgenic mice. NPJ Aging Mech. Dis. 2017, 3, 15.
  74. Wu, Z.; Ni, J.; Liu, Y.; Teeling, J.L.; Takayama, F.; Collcutt, A.; Ibbett, P.; Nakanishi, H. Cathepsin B plays a critical role in inducing Alzheimer’s disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in mice. Brain Behav. Immun. 2017, 65, 350–361.
  75. Leira, Y.; Iglesias-Rey, R.; Gómez-Lado, N.; Aguiar, P.; Campos, F.; D’Aiuto, F.; Castillo, J.; Blanco, J.; Sobrino, T. Porphyromonas gingivalis lipopolysaccharide-induced periodontitis and serum amyloid-beta peptides. Arch. Oral Biol. 2019, 99, 120–125.
  76. Tang, Z.; Liang, D.; Cheng, M.; Su, X.; Liu, R.; Zhang, Y.; Wu, H. Effects of Porphyromonas gingivalis and Its Underlying Mechanisms on Alzheimer-Like Tau Hyperphosphorylation in Sprague-Dawley Rats. J. Mol. Neurosci. 2021, 71, 89–100.
  77. Wu, H.; Ballantyne, C.M. Metabolic Inflammation and Insulin Resistance in Obesity. Circ. Res. 2020, 126, 1549–1564.
  78. Sharma, S.; Tripathi, P. Gut microbiome and type 2 diabetes: Where we are and where to go? J. Nutr. Biochem. 2019, 63, 101–108.
  79. Javed, F.; Warnakulasuriya, S. Is there a relationship between periodontal disease and oral cancer? A systematic review of currently available evidence. Crit. Rev. Oncol. Hematol. 2016, 97, 197–205.
  80. Fang, L.Y.; Wong, T.Y.; Chiang, W.F.; Chen, Y.L. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J. Oral Pathol. Med. 2010, 39, 342–348.
  81. Lee, D.; Wada, K.; Taniguchi, Y.; Al-Shareef, H.; Masuda, T.; Usami, Y.; Aikawa, T.; Okura, M.; Kamisaki, Y.; Kogo, M. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol. Rep. 2014, 31, 1116–1120.
  82. Zhang, Q.Q.; Hu, X.W.; Liu, Y.L.; Ye, Z.J.; Gui, Y.H.; Zhou, D.L.; Qi, C.L.; He, X.D.; Wang, H.; Wang, L.J. CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment. Sci. Rep. 2015, 5, 15948.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Infectious Diseases
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Inseong Hwang
,
View Times: 452
Revisions: 2 times (View History)
Update Date: 06 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Academic Video Service
    Feedback